On the overall market set-up, Ajit Mishra, SVP - Research at Religare Broking reckons to maintain a 'Buy-on-dips' approach, with a preference for relatively stronger stocks across sectors.
As the largest pure-play API/CDMO, Divi's should continue benefiting from custom-synthesis order-book conversion and the structural China+1/BIOSECURE-linked tailwind, analysts believe.
In the March quarter, Divi's Laboratories reported net profit at ₹751 crore, as compared to ₹662 crore a year ago, up 13.4 per cent year-on-year (Y-o-Y)
Nifty outlook for today: Option data suggests a broader trading range in between 23,200 to 24,100 zones while an immediate range between 23,400 to 23,900 levels.